Treatment-Resistant Schizophrenia: Prevalence and Risk Factors

Despite significant progress in the treatment of schizophrenia in recent decades, the evolution of a large rate of patients suffering from this mental disorder is little influenced by treatment [1]. The management of these patients, so-called treatment resistant, constitutes a public health problem. Indeed, these very symptomatic patients often require long periods of hospitalization [2], and their care consumes a disproportionately large share of total cost management of schizophrenia [3].

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  2013-01-16

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.5772/52430
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Expressed Emotion and Psychiatric Relapse

  2015cited by this paper
• Early Onset Schizophrenia

  2013cited by this paper
• Treatment resistant schizophrenia and response to antipsychotics: a review.

  2011cited by this paper
• A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.

  2011cited by this paper
• Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.

  2009cited by this paper
• THÉRAPEUTIQUE Remédiation cognitive et assistants cognitifs numériques dans la schizophrénie Cognitive remediation and cognitive assistive technologies in schizophrenia

  2009cited by this paper
• Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.

  2009cited by this paper
• Predictors of Response to Cognitive Behaviour Therapy in the Treatment of Schizophrenia: A Comparison of Brief and Standard Interventions

  2008cited by this paper
• Schizophrenic patients with polydipsia and water intoxication more often have a form of schizophrenia first described by Kraepelin.

  2007cited by this paper
• Neuroprotection: A New Strategy in the Treatment of Schizophrenia

  2007influential reference
• Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.

  2007cited by this paper
• The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.

  2007cited by this paper
• Very poor outcome schizophrenia: Clinical and neuroimaging aspects

  2007influential reference
• Assessment of childhood disorders

  2007cited by this paper
• Treatment Resistance in Schizophrenia: The Role of Alternative Therapies

  2006influential reference
• Standardized remission criteria in schizophrenia

  2006cited by this paper
• Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

  2005cited by this paper
• Mismatch negativity deficits are associated with poor functioning in schizophrenia patients.

  2005cited by this paper
• Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia.

  2005cited by this paper
• Treatment resistance in schizophrenia

  2005cited by this paper
• Depressed mood and its functional correlates in institutionalized schizophrenia patients.

  2005cited by this paper
• Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

  2005influential reference
• Remission in schizophrenia: proposed criteria and rationale for consensus.

  2005cited by this paper
• Early-onset schizophrenia

  2005cited by this paper
• Reducing the duration of untreated first-episode psychosis: effects on clinical presentation.

  2004cited by this paper
• Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

  2004cited by this paper
• Thalamus size and outcome in schizophrenia.

  2004cited by this paper
• Concept and Management of Treatment Resistant Schizophrenia (TRS)

  2004cited by this paper
• Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

  2004cited by this paper
• Treatment Refractory Schizophrenia

  2004influential reference
• Cognitive deficits as treatment targets in schizophrenia.

  2004cited by this paper
• The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

  2004cited by this paper
• Depression in Kraepelinian schizophrenia.

  2003cited by this paper
• Integrated treatment of schizophrenia.

  2003cited by this paper
• Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.

  2003cited by this paper
• Baseline personality functioning correlates with 6 month outcome in schizophrenia

  2003cited by this paper
• Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.

  2003cited by this paper
• Caudate and putamen volumes in good and poor outcome patients with schizophrenia.

  2003cited by this paper
• Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.

  2002cited by this paper
• Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.

  2002cited by this paper
• Antipsychotic drug treatment in the prodromal phase of schizophrenia.

  2002cited by this paper
• What does electrodermal activity tell us about prognosis in the schizophrenia spectrum?

  2002cited by this paper
• Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

  2002cited by this paper
• Clinical characteristics and risk factors for Kraepelinian subtype of schizophrenia: replication of previous findings and relation to summer birth

  2002cited by this paper
• Management of treatment resistance in schizophrenia.

  2001influential reference
• Longitudinal study of brain morphology in first episode schizophrenia.

  2001cited by this paper
• The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

  2001cited by this paper
• Subtyping schizophrenia according to outcome or severity: a search for homogeneous subgroups.

  2001cited by this paper
• Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum.

  2001cited by this paper
• Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

  2000cited by this paper
• Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome.

  2000cited by this paper
• Sex differences in schizophrenia, a review of the literature.

  2000cited by this paper
• Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres

  2000cited by this paper
• Obstetric complications predict treatment response in first-episode schizophrenia

  1999cited by this paper
• Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• The evolving definition of treatment resistance.

  1999cited by this paper
• MANAGEMENT OF SCHIZOPHRENIA : AN UPDATE

  1998cited by this paper
• Standards of care and clinical algorithms for treating schizophrenia.

  1998cited by this paper
• Expressed emotion and psychiatric relapse: a meta-analysis.

  1998cited by this paper
• Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia

  1998cited by this paper
• Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.

  1998cited by this paper
• The natural history and pathophysiology of treatment resistant schizophrenia.

  1998cited by this paper
• Ventricular enlargement in poor-outcome schizophrenia.

  1998cited by this paper
• Evaluation of treatment-resistant schizophrenia.

  1997cited by this paper
• Practice guideline for the treatment of patients with schizophrenia

  1997cited by this paper
• Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.

  1997cited by this paper
• Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.

  1997cited by this paper
• Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.

  1996cited by this paper
• Relapse in schizophrenia: is there a relationship to substance abuse?

  1996cited by this paper
• Management of treatment-resistant patients with schizophrenia.

  1996cited by this paper
• What are the functional consequences of neurocognitive deficits in schizophrenia?

  1996cited by this paper
• Clozapine eligibility among state hospital patients.

  1996influential reference
• Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings.

  1996cited by this paper
• Psychobiologic Correlates of Treatment Response in Schizophrenia

  1996cited by this paper
• Book Review: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd Edition

  1996influential reference
• Pharmacological treatment strategies in the non-responsive schizophrenic patient

  1996cited by this paper
• Gender differences in schizophrenia: hormonal effect or subtypes?

  1995cited by this paper
• Effects of stringent criteria on eligibility for clozapine among public mental health clients.

  1995cited by this paper
• Conventional antipsychotic medications for schizophrenia.

  1995cited by this paper
• Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.

  1995cited by this paper
• Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.

  1995cited by this paper
• Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi.

  1995cited by this paper
• Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.

  1995cited by this paper
• Notion de schizophrénie résistante

  1995influential reference
• Schizophrenic syndromes associated with treatment response.

  1994cited by this paper
• Treatment of neuroleptic-resistant schizophrenic relapse.

  1993cited by this paper
• Haloperidol response and plasma catecholamines and their metabolites.

  1993cited by this paper
• Predictors of Response to Neuroleptic Treatment in Schizophrenia

  1993influential reference
• Poor neuroleptic response in acutely exacerbated schizophrenic patients

  1993cited by this paper
• Homovanillic acid in the cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment.

  1993cited by this paper
• Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.

  1993cited by this paper
• Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia.

  1992cited by this paper
• Long-term course of hospitalization for schizophrenia: Part I. Risk for rehospitalization.

  1992cited by this paper
• Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

  1992cited by this paper
• Striatal metabolic rate and clinical response to neuroleptics in schizophrenia.

  1992cited by this paper
• Duration of psychosis and outcome in first-episode schizophrenia.

  1992cited by this paper
• The significance of age of onset for schizophrenia.

  1992cited by this paper
• The relationship of structural brain imaging parameters to antipsychotic treatment response: a review.

  1992cited by this paper
• Serum prolactin as a correlate of clinical response to haloperidol.

  1991cited by this paper
• Defining treatment refractoriness in schizophrenia.

  1990cited by this paper

• Sex-informed estrogen receptor modulation in schizophrenia: a male-focused ERβ/GPER1 framework for cognitive and negative symptoms.

  2026cites this paper
• Real-World Treatment of Schizophrenia in Adults With a 22q11.2 Microdeletion: Traitement dans le monde réel de la schizophrénie chez des adultes atteints du syndrome de microdélétion 22q11.2

  2024cites this paper
• Predictors of antipsychotics switching among ambulatory patients with schizophrenia in Ethiopia: a multicenter hospital-based cross-sectional study

  2024cites this paper
• Khat Chewing and Relapse in Peoples With Serious Mental Illness At Amanuel Mental Specialized Hospital: Comparative Study

  2021cites this paper
• Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity.

  2020cites this paper
• A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States

  2020cites this paper
• Childhood maltreatment and treatment outcome in psychotic disorders: a systematic review and meta‐analysis

  2019cites this paper
• Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study

  2019cites this paper
• Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases

  2018cites this paper
• Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment

  2018cites this paper
• The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review.

  2018cites this paper
• The effect of lifetime adversities on resistance to antipsychotic treatment in schizophrenia patients.

  2015cites this paper